Effects of Antiresorptive Drugs on Long Bone Growth, Body Weight Gain, and Serum Lipid Levels in Young Adult Ovariectomized RatsN. Sookvanichsilp*, N. Tad-urai, P. Lawtong and G. Sittithumcharee
-
Although osteoporosis is common among the female elderly, in young adults who are associated with breast cancer treatment or under ovarian abrasion are also at risk to low bone mass. The present study aimed to investigate the benefits in preventing bone deterioration due to estrogen deficiency of antiresorptive drugs, i.e. conjugated equine estrogens (CEE), alendronate and raloxifene in young adult ovariectomized (OVX) rats. Effects of the drugs on body weight gain, serum total cholesterol and serum triglyceride levels were also investigated. Nine-week old female rats were treated orally on the day of ovariectomy with 3 mg/kg/day alendronate, 0.1 mg/kg/day CCE, or 3 mg/kg/day raloxifene for 8 weeks. The results demonstrated that ovariectomy caused a decrease in the growth of long bones as evaluated by the weight, length, volume and calcium content of the femurs and tibias. Ovariectomy also caused an increase in body weight gain and serum total cholesterol while it did not cause any changes in serum triglyceride. Alendronate and CEE, but not raloxifene could effectively prevent bone deterioration due to estrogen deficiency in the OVX rats. Among the three drugs, only alendronate exhibited no significant effects on body weight gain and serum lipids of the OVX rats. Estrogen, although it could delay the body weight increment and had cholesterol-lowering effects, it caused an increase in serum triglyceride. The present results have suggested that in young adult females who are subjected to estrogen deprivation, CEE or alendronate may be effective in preventing the bone from deterioration. However, their adverse events should be taken into account in the long-term use.
Keyword:
Antiresorptive drug, Ovariectomized rat, Bone growth, Body weight gain, Cholesterol, Triglyceride
Download full paper (PDF File size: 1,846.31 KB.)
|